Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.00    -1.50 (-2.10%)
Bid:
69.00
Ask:
71.00
Spread: 2.00 (2.899%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Sch 1 - Readybuy PLC

21 Jul 2006 10:15

AIM21 July 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Readybuy plc COMPANY ADDRESS:Television House, 10-12 Mount Street, Manchester COMPANY POSTCODE:M2 5NT COUNTRY OF INCORPORATION:England and Wales COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Since the Readybuy group's trading activities were terminated in July 2005, the directors of Readybuy have beenexploring the future options available to the Company. The Company's investing strategy is to acquire a companyinvolved in developing enabling technologies, particularly in the defence and bio-chemistry sectors. The Boardbelieves that the proposed acquisition of Avacta meets this investment strategy. Avacta was spun-out from the University of Leeds in January 2004 by its current management team as a biophysicscompany, with the aim of combining the disciplines of physics and biology to develop innovative technologies toaddress needs in the homeland security, pharmaceutical and clinical diagnostic markets. Avacta has two core activities: the development of detection technology platforms designed to meet the needs ofits target markets; and the provision of analytical services relating to the chemical and physical analysis ofmaterials to a range of companies, principally in the pharmaceutical, healthcare and personal care sectors. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):644,857,446 ordinary shares of 0.1p each on First Admission 24,469,898 ordinary shares of 0.1p each on Second AdmissionCAPITAL TO BE RAISED ON ADMISSION:£1,012,500 before expenses, by means of a placing of 45,000,000 ordinary shares of 0.1p each at 2.25p per share FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Directors: Daron Ross Lee (non-executive Chairman) Professor David Alastair Maclaughlin Smith (non-executive director and proposed Chief Executive followingAdmission) Proposed Directors: Dr. Gwynfor Owen Humphreys (proposed non-executive Chairman)Dr. Simon Webster (proposed Chief Scientific Officer)Dr. Kurt Justin Baldwin (proposed Chief Technology Officer)Timothy James Sykes (proposed Chief Financial Officer and proposed Company Secretary)Professor Anthony William Robards (proposed non-executive director)Alan John Aubrey (propose non-executive director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION:Before: Robert Quested (29.76%)Christopher Potts (16.96%)Stephen James (16.09%)Robert Quested, Christopher Potts and Stephen James are also interested in warrants to subscribe for 18,500,000;10,500,000; and 10,000,000 Ordinary Shares respectively. On Admission: Robert Quested (8.93%)Christopher Potts (3.15%)Stephen James (2.99%) The members of the Existing Concert Party, as at the date of this document, together hold 83.71% of the issuedshare capital of the Company, and will, immediately following the Placing and Admission hold 19.84 % thereof.The members of the New Concert Party (being the vendors of Avacta), as at the date of this document, togetherhold 0.96% of the issued share capital of the Company, and will, immediately following the Placing and Admissionhold 74.88% thereof. NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:30 April EXPECTED ADMISSION DATE:8 August 2006 (First Admission)9 August 2006 (Second Admission) NAME AND ADDRESS OF NOMINATED ADVISER:WH Ireland Limited11 St James's SquareManchesterM2 6WH NAME AND ADDRESS OF BROKER:WH Ireland Limited11 St James's SquareManchesterM2 6WH DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Copies of the admission document containing full details about the applicant and the admission of its securitieswill be available free of charge to the public until at least one month after admission at the offices of:- WH Ireland Limited11 St James's SquareManchesterM2 6WH DATE OF NOTIFICATION:21 July 2006 NEW/ UPDATE (see note):New This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jul 20257:00 amRNSManagement Team Appointments
30th Jun 20253:00 pmRNSAppointment of Zeus Capital as Joint Broker
19th Jun 20257:00 amRNSNew Response in Phase 1b Trial
9th Jun 20255:15 pmRNSPosting of Annual Report and Revised Notice of AGM
6th Jun 20257:00 amRNSPreliminary Full Year 2024 Results
4th Jun 20257:00 amRNSAvacta Change in Prelim Date Part 2
28th May 20257:00 amRNSBoard appointments
27th May 20257:00 amRNSUpdate on timing of preliminary results
15th May 20257:00 amRNSNotice of Results
12th May 202512:00 pmRNS-RInvestor Webinar
8th May 20257:30 amRNSBlock Listing Application to AIM
29th Apr 20257:00 amRNSBoard change
28th Apr 20255:52 pmRNSBlock Listing Six Monthly Return
28th Apr 20257:01 amRNSAvacta presents preclinical data at AACR
28th Apr 20257:00 amRNSAvacta presents data from lead candidate at AACR
23rd Apr 20257:00 amRNSIssue of Equity and Total Voting Rights
31st Mar 20257:00 amRNSAvacta Quarterly Update
26th Mar 20257:00 amRNSAvacta Announces Presentations at AACR
25th Mar 20257:00 amRNSAvacta Completes Launch Diagnostics Sale
10th Mar 20257:00 amRNSAvacta to Present at Leerink Healthcare Conference
7th Mar 20258:40 amRNSAvacta announces data update for AVA6000
7th Mar 20257:42 amRNSAvacta to sell Launch Diagnostics
4th Feb 20257:00 amRNSAppointment of Joint Broker
21st Jan 20253:09 pmRNSIssue of Equity and Total Voting Rights
16th Jan 20257:00 amRNSAvacta Announces Data from AVA6000 Phase 1 trial
13th Jan 20257:00 amRNSAvacta Appoints Chief Financial Officer
12th Dec 20247:00 amRNSCompletion of Dose Escalation and RDE Arms
30th Oct 20247:00 amRNSR&D Spotlight focusing on pipeline advances
28th Oct 20247:00 amRNSBlock Listing Six Monthly Return
24th Oct 20247:00 amRNSAvacta Reports Pipeline Avances at EORTC
21st Oct 20244:00 pmRNSIssue of Equity and Total Voting Rights
21st Oct 20247:00 amRNSAvacta and Tempus Enter Strategic Collaboration
17th Oct 20247:00 amRNSAvacta Expands its Pipeline
15th Oct 20247:00 amRNSAvacta appoints Chief Scientific Officer
10th Oct 20247:00 amRNSAvacta Unveils Pipeline Expansion at EORTC 2024
30th Sep 20247:00 amRNSInterim Results
16th Sep 20247:00 amRNSAvacta Reported Updated Phase 1 Data of AVA6000
12th Sep 20247:00 amRNSNotice of Results
9th Sep 20247:00 amRNSAvacta to present clinical data at ESMO Congress
2nd Sep 20243:53 pmRNSDirector/PDMR Shareholdings and TVR
18th Jul 20247:00 amRNSConvertible Bond Payment
26th Jun 20242:46 pmRNSResult of AGM
26th Jun 20247:00 amRNSAGM Business Update
20th Jun 20247:00 amRNSShaun Chilton appointed Non-Executive Chairman
11th Jun 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
31st May 20247:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20247:00 amRNSSuccessful Completion of First Cohort
30th Apr 20247:01 amRNSFull Year Results
30th Apr 20247:00 amRNSBoard Change
26th Apr 20249:51 amRNSBlock listing Interim Return REPLACEMENT

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.